From science — to economy
A venture studio built on a proprietary AI-based investment evaluation system — ARCHITECT.
Thesis
- We find strong scientific projects. Turn them into businesses. Sell to those who can scale them further.
- 3E is our compass: from the ecological soundness of a technology to its economic outcome.
- Vision 2035: a new balance between people, nature, and the economy.
Why now
Scientists are creating breakthrough technologies. Capital is looking for innovative projects worth investing in. We help science become part of the economy, and give capital a tool for fast, precise evaluation.
ARCHITECT
ARCHITECT is a brand of AI platforms for pharma/biotech: from evaluating R&D projects to operational management of manufacturing. Two directions under one brand — different customers, different tasks.
Built to screen portfolio projects without error and forecast their path from idea to economic implementation — cutting the time spent on analysis, novelty checks, and applicability assessment. It has already passed its first real test: it selected PolyGate.
- Search and analysis of scientific documentation
- Scoring of technological readiness and market potential
- Freedom-to-operate and market niches
- Clinical trial forecasting (for health-tech projects)
Customer — the direct market, currently new health-preservation technologies.
Engineering implementation partner — FB Consult, the Fora CRM platform. 20+ years implementing CRM/BI systems, 100+ projects for top Russian and CIS banks, 50+ experts.
Next step — a pilot with the first external partner in the new health-preservation technologies direction.
The brand's second direction. Not R&D evaluation — synchronizing demand, production, and warehouse for a pharmaceutical plant, plus a shipment-readiness check. An independent product: sold directly to pharma manufacturers, not bolted on as a layer inside someone else's CRM/ERP.
- Consensus — synchronizing demand, production, and warehouse (IBP/S&OP)
- Legitimacy — checking marking codes and records before shipment
Status — direction opened in September 2026, at the start of development.
PolyGate
An active-substance delivery platform built on the chitosan biopolymer. Three independently validated preclinical products, built on solvent-free mechanochemical synthesis.
| Product | Solves | Result (preclinical) |
|---|---|---|
| Oral insulin "Hitalin" | Replaces injections with tablets for type 1 diabetes | Up to 78% blood glucose reduction; active only at elevated glucose levels, does not induce hypoglycemia at normal blood sugar; no toxicity or mutagenicity detected |
| Chitosan-isoniazid | Boosts tuberculosis therapy | 3x the activity of isoniazid alone; lower toxicity; no mutagenicity detected |
| Transdermal KDTsVIM antidote | Carbon monoxide antidote, no injections or hospitalization | Active within 30 minutes; blood residence time 6x longer than intramuscular administration; safe dose margin 20x the therapeutic dose; no mutagenicity detected |
Science lead — Sergey Sergeevich Markin, MD, DSc, professor. Co-creator of the "Fortelysin" thrombolytic drug (used in over 200,000 patients); author of 100+ publications and 32 patents.
Status — project entity registered, OOO "PolyGate", June 18, 2026.
Next step — patent application on September 16, 2026, followed by publications in international journals for each product and updated pharmacodynamics testing.
Goal — exit within 18 months: sale to a strategic buyer.
Proof the model works
- ARCHITECT isn't a hypothesis: it's the one that selected PolyGate for the portfolio
- The same cycle applied twice
- Capital from PolyGate funds ARCHITECT through to the second exit
Goals
Team
Entry points for partners
| Audience | What we offer | |
|---|---|---|
| Pharma/biotech corporations | A PolyGate platform license — access to three product lines at once | Write → |
| Health-preservation technology companies and developers, investment funds | An ARCHITECT pilot — scoring your own R&D projects instead of evaluating from zero | Write → |
| Pharma manufacturers (plants) | Ordanix — operational sync of demand, production, and warehouse; marking checks before shipment (in development) | Write → |
| Founders with a scientific asset | We take on capitalization, legal structure, and finding a buyer — you focus on the science | Write → |
| Talent and experts | Join ARCHITECT and Ordanix development at the very start, with influence over the product architecture | Write → |